UK markets open in 3 hours 10 minutes
  • NIKKEI 225

    26,702.02
    +531.72 (+2.03%)
     
  • HANG SENG

    23,606.45
    -200.55 (-0.84%)
     
  • CRUDE OIL

    87.10
    +0.49 (+0.57%)
     
  • GOLD FUTURES

    1,797.20
    +4.10 (+0.23%)
     
  • DOW

    34,160.78
    -7.31 (-0.02%)
     
  • BTC-GBP

    27,744.31
    +826.36 (+3.07%)
     
  • CMC Crypto 200

    843.24
    +23.73 (+2.90%)
     
  • ^IXIC

    13,352.78
    -189.34 (-1.40%)
     
  • ^FTAS

    4,230.83
    +38.13 (+0.91%)
     

Transparency notification received from Tolefi SA and related persons (Article 14 §1 of the Law of 2 May 2007)

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • CLYYF
  • CYAD

MONT-SAINT-GUIBERT, Belgium, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification dated December 17, 2021 indicating that Tolefi SA and related persons have crossed together the statutory threshold of 20%, holding 18,65% of the voting rights of the company as of December 8, 2021.

Content of the Notification:

  • Reason of the Notification:
    Downward passive crossing of the 20% threshold
    Downward passive crossing by persons acting in concert

  • Notification by:
    Persons acting in concert

  • Persons subject to the notification requirement:
    Tolefi SA, Chaussée de Waterloo 1589D, 1180 Uccle
    Serge Goblet
    Isabelle Thoumyre
    Jérôme Goblet
    Jean-Daniel Goblet

  • Transaction date
    December 8, 2021

  • Threshold that is crossed (in %)
    20

  • Denominator
    24.961.981

  • Notified details:

A) Voting Rights

Previous
notification

After the Transaction

#of voting rights

# of voting rights

% of voting rights

Holders of voting rights

Linked to the
securities

Not linked to the
securities

Linked to the
securities

Not linked to the
securities

Tolefi SA

4.591.402

4.591.402

18,39%

Serge Goblet

56.180

56.180

0,23%

Isabelle Thoumyre

7.300

7.300

0,03%

Jérôme Goblet

250

250

0,00%

Jean-Daniel Goblet

384

384

0,00%

TOTAL

4.655.516

4.655.516

18,65%

  • Chain of controlled undertakings through which the holdings is effectively held
    Tolefi SA is 100% controlled by Serge Goblet, Isabelle Thoumyre, Jérôme and Jean-Daniel Goblet.

Miscellaneous

  • The Press Release may be consulted on the website of Celyad Oncology via this link.

    The notification can be consulted on the website of Celyad Oncology via this
    link.

  • Contact person(s):
    By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): investors@celyad.com.

About Celyad Oncology SA

Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.

Forward-looking statements

This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the clinical activity and safety and tolerability of CYAD-211 and expectations regarding enrollment and the announcement of additional clinical data, and the clinical activity and safety and tolerability of the CYAD-02 and CYAD-101 programs. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in the latest Annual Report on Form 20-F filed with the SEC and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

Investor and Media Contacts:

Sara Zelkovic
Communications & Investor Relations Director
Celyad Oncology
investors@celyad.com

Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

Source: Celyad Oncology SA


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting